Phase 1 Results of the First-in-Class CXCR1/2 Inhibitor SX-682 in Patients with Hypomethylating Agent Failure Myelodysplastic Syndromes Meeting Abstract

cited authors

  • Sallman, David A.; DeZern, Amy E.; Gayle, Arlene A.; Kahn, Stuart J.; Padron, Eric; Lancet, Jeffrey E.; Kuykendall, Andrew; Sweet, Kendra; Chan, Onyee; Maeda, Dean Y.; Schuler, Aaron D.; Zebala, John A.; Komrokji, Rami S.

authors

Publication Date

  • November 15, 2022

webpage

published in

category

start page

  • 2070

end page

  • 2072

volume

  • 140